These revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio.
News & Analysis: Acadia Pharmaceuticals
Unexpected phase 3 clinical trial data has investors smiling.
How much longer can they keep it up?
Acadia's stock has taken flight this year.
Lackluster sales of Nuplazid could finally take flight next year.
Acadia's flagship drug notched a key late-stage win today.
Read why AT&T and ACADIA Pharma stood out on a roller-coaster day for the broader markets.
Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up.
Nuplazid picked up momentum in the second quarter, enabling Acadia to up its full-year 2019 outlook.
ACAD earnings call for the period ending June 30, 2019.